References
- Heres S, Lambert M, Vauth R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatr 2014;29:1409–13
- Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatr 2016;77:764–71
- Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin 2011;27:713–30
- Holder SD, Wayhs A. Schizophrenia. Am Fam Physician 2014;90:775–82
- Biagi E, Capuzzi E, Colmegna F, et al. Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly. Adv Ther 2017;34:1036–48
- Chong HY, Chaiyakunapruk N, Wu DBC, et al. Global economic burden of schizophrenia: a systematic review. Value Health 2014;17:A767
- Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet 2016;388:86–97
- Chong HY, Teoh SL, Wu DB, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat 2016;12:357–73
- Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc 2009;7:4
- Schennach R, Riedel M, Musil R, et al. Treatment response in first-episode schizophrenia. Clin Psychopharmacol Neurosci 2012;10:78–87
- Olivares JM, Sermon J, Hemels M, et al. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Pyschiatry 2013;12:32
- Schoenbaum M, Sutherland JM, Chappel A, et al. Twelve-month health care use and mortality in commercially insured young people with incident psychosis in the United States. Schizophr Bull 2017;43:1262–72
- Lieberman JA, Dixon LB, Goldman HH. Early detection and intervention in schizophrenia: a new therapeutic model. JAMA 2013;310:689–90
- Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatr 2015;72:822–9
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association; 2013
- Rubin DT, Kane S, Jaganathan S, et al. Web Exclusive: Real-world anti-TNF dose escalation in patients with Crohn’s disease. Am J Pharm 2015;7:e135–40
- Campagna EJ, Muser E, Parks J, et al. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication. J Managed Care Spec Pharm 2014;20:756–66
- Fitch K, Iwasaki K, Villa KF. Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benefit 2014;7:18
- Saloner B, Lê Cook B. An ACA provision increased treatment for young adults with possible mental illnesses relative to comparison group. Health Affairs 2014;33:1425–34
- Offord S, Wong B, Mirski D, et al. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ 2013;16:231–9
- Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nordic J Psychiatr 2014;68:416–27
- Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: Evaluating the evidence. J Clin Psychiatr 2016;77(suppl 3):1–24
- Offord S, Lin J, Mirski D, et al. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther 2013;30:286–97
- Markowitz M, Karve S, Panish J, et al. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. BMC Psychiatry 2013;13:246
- Starr HL, Bermak J, Mao L, et al. Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: an exploratory analysis of the PRIDE study. Schizophr Res 2018;194:39–46
- Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol 2014;17:1083–93